ArticleSurgical endoscopy2025
Biodegradable biliary stents in pancreaticoduodenectomy for mitigating biliary complications in high-risk anastomoses.
Article in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Robotic transanastomotic stenting via Witzel technique in complex hepaticojejunostomy for biliary tract tumors.Surgical endoscopy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiliary complications are a significant challenge in pancreaticoduodenectomy (PD), particularly in patients with small bile ducts. This study evaluated the safety and efficacy of biodegradable biliary stents (BS) in reducing biliary complications and improving outcomes in patients undergoing PD.
methodsThis retrospective study included 80 patients with a high risk of biliary fistula undergoing PD at a single high-volume center. Patients were divided into two groups: those who received a biodegradable biliary stent (BS group, n=40) and a retrospective cohort of patients who underwent biliary anastomosis without a stent (nBS group, n=40). A 1:1 propensity score matching (PSM) was performed based on key clinical and surgical variables to reduce selection bias. The primary outcome was the incidence of biliary fistulas. Cost analysis was also conducted.
resultsAfter PSM, 30 matched pairs were analyzed. The BS group had significantly shorter operative times for robotic biliary anastomosis (14 [12-18] vs. 22 [20-27] minutes, p<0.001). No biliary fistulas occurred in the BS group, compared to 3 cases (10%) in the matched nBS group (p=0.039). Comprehensive Complication Index scores were lower in the BS group (21.2 [0-62] vs. 24 [0-88], p=0.047), suggesting reduced overall morbidity. One early biliary stricture occurred in the BS group and one late stricture in the nBS group. No deaths occurred in the BS group, while one patient (3.3%) died in the nBS group (p=0.317). Cost analysis showed no statistically significant differences but suggested a trend favoring stent use.
conclusionBiodegradable biliary stents reduce biliary fistulas and operative time in PD while demonstrating a favorable safety profile. Early complications such as transient jaundice occurred at low rates, the absence of long-term biliary strictures supports their use as a valuable tool in high-risk biliary anastomoses. Multicenter studies with long-term follow-up are necessary to validate these findings and assess cost-effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.